ERBB2 and breast cancer: Of these 31 BC patients, 19 patients were HER2+/HR± and all of them received HER2‐targeted drug trastuzumab and/or lapatinib together with chemotherapy, except for one (BC31) who received hormonal therapy plus chemotherapy.